ER-100 Enters Optic Neuropathy Trial - Takeaways - MDSpire

ER-100 Enters Optic Neuropathy Trial

Life Biosciences doses first patient in epigenetic restoration clinical trial

  • July 24, 2026

  • 2 min

Share

  • 1

    Life Biosciences has initiated a Phase 1 clinical trial for ER-100, targeting optic neuropathies such as open-angle glaucoma and NAION.

  • 2

    The trial will assess the safety and tolerability of ER-100, with endpoints focused on visual function.

  • 3

    ER-100 is the first candidate from Life Biosciences’ Epigenetic Restoration platform, utilizing three transcription factors.

  • 4

    Current treatments for open-angle glaucoma do not address retinal ganglion cell damage, while NAION has no approved therapies.

  • 5

    David Sinclair stated that the study is a significant opportunity to test the impact of restoring epigenetic information on human disease.

Original Source(s)

ER-100 Enters Optic Neuropathy Trial

  • July 24, 2026

Related Content

A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.

OLN324: Why Size May Matter

David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.

Endogenous Endophthalmitis and Missed Diagnoses

Retrospective study describes how endogenous endophthalmitis often presents without systemic symptoms

  • July 21, 2026

  • 3 min